Ceruloplasmin
Based on 1 Customer Validation
Ceruloplasmin is a copper-binding ferroxidase and serum copper carrier. Ceruloplasmin promotes FPN1-mediated iron export by catalyzing ferrous iron oxidation, maintains the protein stability of ferroportin, and assists transferrin and lactoferrin in completing iron binding; it regulates HIF, AMPK, PPARα, and PGC1α, exerting antioxidant effects and inhibiting ferroptosis (Ferroptosis). Ceruloplasmin can be used in research on posthemorrhagic anemia, hemolytic anemia, neurodegenerative diseases, NAFLD, metabolic diseases, hereditary aceruloplasminemia, hepatocellular carcinoma, and ischemia-reperfusion injury.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 9031-37-2
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
AMPK アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[6]|
AMPK |
PPARα |
PGC1α |
体外実験
Ceruloplasmin overexpression inhibits Erastin/RSL3-induced ferroptosis in HepG2 and Hep3B cells, reducing iron, MDA, and lipid ROS by approximately half[9].
Ceruloplasmin inhibits Erastin/RSL3-induced ferroptosis in HepG2 and Hep3B cells in an FPN-dependent manner[9].
Ceruloplasmin (0.25‑1.25 μM) exhibits ferroxidase activity of 0.8 s⁻¹ at 25 °C in the absence of Cl⁻ and 1.2 s⁻¹ in the presence of 100 mM NaCl[5].
Ceruloplasmin enhances PPARα target promoter activity and PGC1α/PPARα promoter recruitment upon depletion in the AML12/hepatocyte reporter gene assay, whereas Ceruloplasmin overexpression inhibits PPAR agonist GW9578 (HY-117196)-induced reporter gene activity[6].
Ceruloplasmin reduces the SCO1-AMPK interaction upon overexpression in HEK293T Co-IP experiments, without directly entering the SCO1-LKB1-AMPK complex[6].
Ceruloplasmin expression is inhibited by Erastin (HY-15763) and RSL3 (HY-100218A) in HepG2 and Hep3B cells, and copper supplementation does not alter this downregulation[9].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (approximately 3 months on diet; body mass 214 g)[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; single injection
-
Result:Stabilized HIF-1α and HIF-2α in liver and brain on day 1 only.
Failed to stabilize HIF-1α or HIF-2α on days 2, 3, 4, and 5.
-
Animal Model:Wistar (approximately 3 months on AgCl diet; body mass 212 g)[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; single injection
-
Result:Stabilized HIF-1α and HIF-2α in liver and brain on day 1 only.
Failed to stabilize HIF-1α or HIF-2α on days 2, 3, 4, and 5.
-
Animal Model:Hartley (female; 250-299 g)[3]
-
Dosage:20 mg/kg
-
Administration:i.p.; 18 h apart; days 13 and 14
-
Result:Increased ceruloplasmin oxidase activity from 63 units/dl in noninjected ascorbic acid-adequate guinea pigs to 82 units/dl in ascorbic acid-injected ascorbic acid-adequate guinea pigs, a 30% mean increase.
-
Animal Model:C57BL/6J (male)[6]
-
Dosage:Ad-shCp 1 × 109 pfu per mouse
-
Administration:i.v. (tail vein); for 3 weeks
-
Result:Reduced liver weight, ectopic lipid accumulation in the liver, and plasma free fatty acids.
Showed liver diacylglycerides, free fatty acids, and triglycerides were substantially reduced.
Improved glucose clearance and insulin sensitivity.
Observed no differences in body weight or food intake.
-
Animal Model:Cpflox/flox[6]
-
Dosage:AAV2/9-TBG-Cre-GFP 1 × 1012 vector genomes per mouse
-
Administration:i.v. (tail vein)
-
Result:Displayed lower ectopic hepatic lipid accumulation and substantially less insulin resistance.
Observed no differences in glucose tolerance.
-
Animal Model:Sprague-Dawley (male, 230-270 g)[10]
-
Dosage:60 mg/kg
-
Administration:intraperitoneal; once; 30 min before flap elevation
-
Result:Reduced necrosis area to 14.4% of flap on postoperative day 7.
Increased catalase to 0.15 U/mg protein.
Decreased MDA to 0.8 nmol/mg protein.
Showed edema score 0.8, necrosis score 0.25, polymorphonuclear leukocyte infiltration score 1.25, collagen density score 1.57, fibroblast proliferation score 1.75, and vascular density score 1.37.
Showed epidermal thickness 22.24 μm.
Specific Activity
20 - 75 U/mg protein
Unit Definition
One unit is defined as the amount of enzyme that will cause a ΔA550 of 0.01 per min using N,Ndimethyl-p-phenylenediamine as substrate at pH 5.5 and 37°C, in a 7 mL reaction volume.
化学情報
-
CAS 番号 9031-37-2
-
性状 Solid
-
Color Off-white to light yellow
-
SMILES
[Ceruloplasmin]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (285 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Ceruloplasmin 関連分類
HY-P2777 関連分類
Powered by Bioz